Kymera Director Granted $744K in Stock Options, Vesting Within One Year

Kymera Therapeutics Director Victor Sandor received a stock option grant on June 25, 2025, according to a Form 4 filing.

Rhea-AI Filing Summary

Kymera Therapeutics Director Victor Sandor received a stock option grant on June 25, 2025, according to a Form 4 filing. The grant consists of 16,000 stock options with an exercise price of $46.47 per share.

Key details of the stock option grant:

• The options expire on June 24, 2035
• Vesting occurs at the earlier of June 25, 2026 or the next annual stockholder meeting
• The derivative securities are held directly by the reporting person
• The transaction was reported through an attorney-in-fact on June 26, 2025

This grant appears to be part of the company's director compensation program, with a one-year cliff vesting schedule tied to continued board service.

Insider Trade Summary

Grant/Award: 16,000 shares

Grant/Award 1 txn

Insider Sandor Victor

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 16,000 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 25, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options were granted to Victor Sandor at KYMR on June 25, 2025?

Victor Sandor was granted 16,000 stock options with an exercise price of $46.47 per share. These options were granted on June 25, 2025, and expire on June 24, 2035.

What is the vesting schedule for Victor Sandor's KYMR stock options granted in June 2025?

The stock options will vest in full upon the earlier of two dates: (i) June 25, 2026 or (ii) the date of the next annual meeting of Kymera Therapeutics' stockholders.

What position does Victor Sandor hold at KYMR?

According to the Form 4 filing, Victor Sandor serves as a Director at Kymera Therapeutics, Inc.

How much did Victor Sandor pay for the KYMR stock options granted in June 2025?

Victor Sandor received the stock options at no cost ($0), though they have an exercise price of $46.47 per share if he chooses to exercise them in the future.

When do Victor Sandor's June 2025 KYMR stock options expire?

The stock options expire on June 24, 2035, giving them a 10-year term from the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2025 - 09:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandor Victor

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$46.47	06/25/2025		A		16,000		(1)	06/24/2035	Common Stock	16,000	$0	16,000	D

Explanation of Responses:

1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 25, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders.

	/s/ Bruce Jacobs, as Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.